Novel diagnostics & biomarkers for DLBCL and CTCL

3 Views
administrator
administrator
08/09/23

In this session, Thomas Habermann, MD, of the Mayo Clinic, Rochester, MI, chairs a discussion with Bjoern Chapuy, PhD, MD, from the Dana-Farber Cancer Institute, Boston, MA, and Nicolas Ortonne, MD, PhD, of Henri Mondor University Hospital, Créteil, France. The group explore actionable genetic signatures for diffuse large B-cell lymphoma, and biomarkers for the diagnosis and treatment of cutaneous T-cell lymphoma. This discussion was recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France.

Show more
0 Comments Sort By

    No comments found

    Facebook Comments

    Up next

    Biomarkers of amyloidosis
    00:02:26
    Biomarkers of amyloidosis
    administrator
    1 Views
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    00:03:06
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    administrator
    3 Views
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    00:02:51
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    administrator
    2 Views
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    00:02:30
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    administrator
    3 Views
    The CTCL diagnosis journey
    00:00:20
    The CTCL diagnosis journey
    administrator
    5 Views
    Unmet needs for late-stage CTCL
    00:01:10
    Unmet needs for late-stage CTCL
    administrator
    3 Views
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    00:01:16
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    administrator
    2 Views
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    00:01:35
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    administrator
    4 Views
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    00:08:49
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    administrator
    10 Views
    Pre-clinical activity of tipifarnib in CTCL
    00:02:12
    Pre-clinical activity of tipifarnib in CTCL
    administrator
    4 Views
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    00:04:47
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    administrator
    3 Views
    CTCL 06 2017
    02:28:08
    CTCL 06 2017
    administrator
    1 Views
    Brentuximab vedotin for CTCL
    00:02:30
    Brentuximab vedotin for CTCL
    administrator
    2 Views
    Clonal evolution in patients with CTCL
    00:02:24
    Clonal evolution in patients with CTCL
    administrator
    3 Views
    RESMAIN: HDAC inhibitor resminostat for CTCL
    00:01:23
    RESMAIN: HDAC inhibitor resminostat for CTCL
    administrator
    1 Views
    Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
    00:13:18
    Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
    administrator
    2 Views
    Unmet needs and upcoming therapies in CTCL
    00:03:34
    Unmet needs and upcoming therapies in CTCL
    administrator
    2 Views
    Novel Therapies for CTCL - Andrei Shustov, MD
    01:00:41
    Novel Therapies for CTCL - Andrei Shustov, MD
    administrator
    3 Views
    Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients
    00:01:02
    Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients
    administrator
    4 Views